Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

Dow Jones

Feb 28, 2025

By Connor Hart

Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to "No Action Indicated," the company said.

"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection," the maker of over-the-counter pharmaceuticals said Thursday.

A "no action" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A "voluntary action" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action.

The reclassification comes after the FDA inspected the facility in October and November.

Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier.

Adjusted per-share earnings came in at 93 cents, just ahead of the 92 cents that analysts surveyed by FactSet expected.

Net sales slipped 1.6%, to $1.14 billion, below the $1.19 billion that analysts modeled.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

February 27, 2025 18:37 ET (23:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514097352"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514097352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514097352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514097352","market":"sh","top_or_hot":-1,"title":"Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to \"No Action Indicated,\" the company said. \n</p>\n<p>\n  \"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection,\" the maker of over-the-counter pharmaceuticals said Thursday. \n</p>\n<p>\n  A \"no action\" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A \"voluntary action\" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action. \n</p>\n<p>\n  The reclassification comes after the FDA inspected the facility in October and November. \n</p>\n<p>\n  Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted per-share earnings came in at 93 cents, just ahead of the 92 cents that analysts surveyed by FactSet expected. \n</p>\n<p>\n  Net sales slipped 1.6%, to $1.14 billion, below the $1.19 billion that analysts modeled. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2025 18:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-28 07:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to \"No Action Indicated,\" the company said. \n</p>\n<p>\n  \"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection,\" the maker of over-the-counter pharmaceuticals said Thursday. \n</p>\n<p>\n  A \"no action\" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A \"voluntary action\" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action. \n</p>\n<p>\n  The reclassification comes after the FDA inspected the facility in October and November. \n</p>\n<p>\n  Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted per-share earnings came in at 93 cents, just ahead of the 92 cents that analysts surveyed by FactSet expected. \n</p>\n<p>\n  Net sales slipped 1.6%, to $1.14 billion, below the $1.19 billion that analysts modeled. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 27, 2025 18:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGO","symbol_name":"百利高","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514097352","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514097352","pubTimestamp":1740699420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to \"No Action Indicated,\" the company said.\"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection,\" the maker of over-the-counter pharmaceuticals said Thursday.A \"no action\" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A \"voluntary action\" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action.The reclassification comes after the FDA inspected the facility in October and November.Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier.Adjusted per-share earnings came in at 93 cents, just ahead o","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRGO":"百利高"},"translate_title":"Perrigo因第四季度利润和收入下降而被FDA重新分类","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGO":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Perrigo received notice from the Food and Drug Administration that its infant-formula facility in Wisconsin would be reclassified to \"No Action Indicated,\" the company said. \n\n\n  \"This marks a substantial advancement from the facility's 'Voluntary Action Indicated' status existing prior to this 2024 inspection,\" the maker of over-the-counter pharmaceuticals said Thursday. \n\n\n  A \"no action\" indication means that no objectionable conditions or practices were found during an inspection, according to the FDA. A \"voluntary action\" indicated means that objectionable conditions or practices were found, though the agency won't take or recommend any administrative or regulatory action. \n\n\n  The reclassification comes after the FDA inspected the facility in October and November. \n\n\n  Also on Thursday, Perrigo posted a loss of $44.5 million, or 32 cents a share, in the fourth quarter, compared with a loss of $32.3 million, or 24 cents a share, a year earlier. \n\n\n  Adjusted per-share earnings came in at 93 cents, just ahead of the 92 cents that analysts surveyed by FactSet expected. \n\n\n  Net sales slipped 1.6%, to $1.14 billion, below the $1.19 billion that analysts modeled. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 18:37 ET (23:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}